Fostemsavir

Drug Profile

Fostemsavir

Alternative Names: BMS 626529 prodrug; BMS-663068; GSK 3684934; HIV attachment inhibitor - ViiV Healthcare; Temsavir prodrug

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; ViiV Healthcare
  • Class 2 ring heterocyclic compounds; Antiretrovirals; Phosphoric acid esters; Piperazines; Pyridines; Pyrroles; Small molecules; Triazoles
  • Mechanism of Action Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 08 Aug 2016 Bristol-Myers Squibb plans a phase I bioavailability trial in Healthy volunteers in USA (PO, Tablet) (NCT02859259)
  • 30 Jun 2016 Bristol-Myers Squibb completes a phase I trial for HIV-1 infections (Treatment experienced) in USA (NCT02666001)
  • 31 May 2016 Bristol-Myers Squibb completes a phase I pharmacokinetic trial in HIV-1 infections (In volunteers) in USA (NCT02674581)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top